| Adenosine 2A Receptor Antagonism and AIH in ALS (NCT05377424) | University of Florida | 2022-06-21 |
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (NCT05357950) | NeuroSense Therapeutics Ltd. | 2022-05-31 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS (NCT05151471) | Tanabe Pharma America, Inc. | 2022-01-11 |
| Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis (NCT05163886) | OrphAI Therapeutics | 2021-12-23 |
| NF-κB Inhibition in Amyotrophic Lateral Sclerosis (NCT05031351) | Sunnybrook Health Sciences Centre | 2021-10-19 |
| Digital Tools for Assessment of Motor Functions and Falls in ALS (NCT05271435) | Milton S. Hershey Medical Center | 2021-10-01 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis (NCT04948645) | AbbVie | 2021-09-22 |
| PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease (NCT04396873) | National Institute of Mental Health (NIMH) | 2021-08-17 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS (NCT04987671) | Amylyx Pharmaceuticals Inc. | 2021-08-05 |
| Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients (NCT05287958) | Beth Israel Deaconess Medical Center | 2021-07-15 |
| Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (NCT04931862) | Wave Life Sciences USA, Inc. | 2021-06-28 |
| Multimodal Imaging Outcome Measures for ALS (Image ALS) (NCT04490096) | University of Pennsylvania | 2021-02-25 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS (NCT04569084) | Shionogi | 2020-11-13 |
| Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care (NCT04138095) | Riverview Health Centre | 2020-10-01 |
| Remote Pulmonary Function Testing and Nurse Coaching in ALS (NCT04490148) | Milton S. Hershey Medical Center | 2020-07-01 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants (NCT04248465) | Alexion Pharmaceuticals, Inc. | 2020-03-30 |
| Trial of Oxaloacetate in ALS (NCT04204889) | Omar Jawdat | 2020-03-17 |
| A Study to Explore the Role of Gut Flora in ALS (NCT04150809) | ProgenaBiome | 2020-03-02 |
| Respiratory Muscle Training (RMT) in ALS (NCT04224961) | Duke University | 2020-01-14 |
| Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS (NCT04165850) | NeuroSense Therapeutics Ltd. | 2019-11-25 |
| Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) (NCT04259255) | Shionogi | 2019-10-21 |
| Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products (NCT03886753) | Children's Hospital of Philadelphia | 2019-05-15 |
| Speech Analysis in ALS Patients (NCT03868345) | Barrow Neurological Institute | 2019-02-18 |
| Amyotrophic Lateral Sclerosis (ALS) Families Project (NCT03865420) | Columbia University | 2018-09-11 |
| rTMS in Treatment of Spasticity (NCT04054141) | Hospital for Special Surgery, New York | 2018-09-01 |
| A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) (NCT03506425) | Richard Bedlack, M.D., Ph.D. | 2018-06-21 |
| Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis (NCT03472950) | University of Kansas Medical Center | 2018-06-11 |
| Open Label Extension Study of AMX0035 in Patients With ALS (NCT03488524) | Amylyx Pharmaceuticals Inc. | 2018-03-29 |
| Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis (NCT03457753) | Aquestive Therapeutics | 2018-03-01 |
| Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS (NCT03520517) | Biohaven Pharmaceuticals, Inc. | 2018-02-02 |
| Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS (NCT03373981) | Hospital for Special Surgery, New York | 2017-11-29 |
| A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT03272503) | University of Calgary | 2017-10-27 |
| Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (NCT03268603) | Mayo Clinic | 2017-10-10 |
| A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS (NCT03324399) | Avera McKennan Hospital & University Health Center | 2017-06-01 |
| Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) (NCT03019419) | Tokyo Medical University | 2017-04-24 |
| Deep Phenotyping in Patients With ALS (NCT02819765) | Barrow Neurological Institute | 2017-02-07 |
| Effect of MD1003 in Amyotrophic Lateral Sclerosis (NCT03114215) | MedDay Pharmaceuticals SA | 2016-06-29 |
| Genomic Translation for Amyotrophic Lateral Sclerosis Care (NCT02795897) | Columbia University | 2016-06-08 |
| T Cell Phenotypes in Amyotropic Lateral Sclerosis (ALS), Influence of Vitamin D (NCT02756104) | University Hospital, Montpellier | 2016-06-07 |
| Neurologic Stem Cell Treatment Study (NCT02795052) | MD Stem Cells | 2016-06-01 |
| Safety of Caprylic Triglycerides in ALS: A Pilot Study (NCT02716662) | Weill Medical College of Cornell University | 2016-01-01 |
| Spinal Interneuron Excitability in ALS (NCT02429492) | Institut National de la Santé Et de la Recherche Médicale, France | 2015-11-16 |
| A Trial of Tocilizumab in ALS Subjects (NCT02469896) | Barrow Neurological Institute | 2015-11-01 |
| A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) (NCT02525471) | Sabrina Paganoni, M.D. | 2015-10-01 |
| Assessment of Voluntary and Reflex Cough in Patients With ALS (NCT02495571) | IRCCS San Camillo, Venezia, Italy | 2015-10-01 |
| Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis (NCT02457715) | Duke University | 2015-07-01 |
| ALS/MND Natural History Study Data Repository (NCT05966038) | Massachusetts General Hospital | 2015-04-01 |
| MRI Biomarkers in ALS (NCT02405182) | University of Alberta | 2014-09-01 |
| Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis (NCT02228915) | University of North Carolina, Chapel Hill | 2014-08-01 |
| Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis (NCT01992029) | University Hospital, Bordeaux | 2014-06-17 |
| Neuromuscular Ultrasound in ALS (NCT01785550) | Duke University | 2013-02-01 |
| Evaluation of Metabolomic Analysis in Early Diagnosis of ALS (NCT01962311) | University Hospital, Tours | 2013-02-01 |
| Coping Effectiveness Training for ALS (NCT01583205) | Research Foundation for Mental Hygiene, Inc. | 2012-04-01 |
| Biological Sample Collection for Research and Biobanking (NCT04270604) | New York Stem Cell Foundation Research Institute | 2012-02-06 |
| A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers (NCT01495390) | Massachusetts General Hospital | 2011-11-01 |
| ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis (NCT01393444) | University of Pittsburgh | 2011-05-01 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis (NCT01363401) | Corestemchemon, Inc. | 2011-02-01 |
| Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis (NCT01124292) | Georgia Institute of Technology | 2010-05-01 |
| Optimizing NIPPV Use for Patients With ALS (NCT01035476) | University of Pittsburgh | 2009-12-01 |
| Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS) (NCT03366506) | Hadassah Medical Organization | 2009-03-09 |
| Talampanel for Amyotrophic Lateral Sclerosis (ALS) (NCT00696332) | Teva Branded Pharmaceutical Products R&D, Inc. | 2008-09-01 |
| Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS) (NCT00809224) | University of Michigan | 2008-05-01 |
| Clinical Trial Ceftriaxone in Subjects With ALS (NCT00349622) | Massachusetts General Hospital | 2006-07-01 |
| Phase II Study Using Thalidomide for the Treatment of ALS (NCT00140452) | Dartmouth-Hitchcock Medical Center | 2005-02-01 |
| Exposure to Neurotoxins as Risk Factors for ALS (NCT00340301) | National Institute of Environmental Health Sciences (NIEHS) | 2003-06-03 |
| National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank (NCT00076154) | US Department of Veterans Affairs | 2003-01-01 |
| Intermediate Expanded Access Protocol CNMAu8.EAP04 (NCT06408727) | Clene Nanomedicine | |
| Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT03537807) | Biohaven Pharmaceuticals, Inc. | |
| Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (NCT06743776) | Mayo Clinic | |